UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation

Cancers, 2022-06, Vol.14 (12), p.2962

2022

Volltextzugriff (PDF)

Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?

Cancers, 2022-04, Vol.14 (8), p.1856

2022

Volltextzugriff (PDF)

Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis

Cancers, 2023-08, Vol.15 (17), p.4264

2023

Volltextzugriff (PDF)

Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review

Cancers, 2022-03, Vol.14 (6), p.1428

2022

Volltextzugriff (PDF)

Effects of Immunotherapy on Quality-of-Life Outcomes in Patients with Gastroesophageal Cancers: A Meta-Analysis of Randomized Controlled Trials

Healthcare (Basel), 2024-08, Vol.12 (15), p.1496

2024

Volltextzugriff (PDF)

Association between Environmental Temperature and Survival in Gastroesophageal Cancers: A Population Based Study

Cancers, 2023-12, Vol.16 (1), p.74

2023

Volltextzugriff (PDF)

A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm

Cancer, 2023-09, Vol.129 (18), p.2773-2788

2023

Volltextzugriff (PDF)

Targeting the tumor microenvironment to improve clinical outcomes in triple negative breast cancer patients and bridge the current disparity gap

Frontiers in immunology, 2024-07, Vol.15, p.1428118

2024

Volltextzugriff (PDF)

Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient

Curēus (Palo Alto, CA), 2021-11

2021

Volltextzugriff (PDF)

Higher inflammatory response in hepatocellular carcinoma is associated with immune cell infiltration and a better outcome

Hepatology international, 2024-08, Vol.18 (4), p.1299-1309

2024

Volltextzugriff (PDF)

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience

Frontiers in oncology, 2022-10, Vol.12, p.1012391

2022

Volltextzugriff (PDF)

Predictors of Complete Pathological Response with Chemoimmunotherapy in Triple-Negative Breast Cancer: A Meta-Analysis

Onco, 2023-12, Vol.4 (1), p.1-14

2023

Volltextzugriff (PDF)

Undiagnosed Acquired Hemophilia A: Presenting as Recurrent Gastrointestinal Bleeding

Curēus (Palo Alto, CA), 2020-09

2020

Volltextzugriff (PDF)

Bad science in the time of COVID-19

Cancer Research, Statistics, and Treatment, 2020-01, Vol.3 (3), p.434-436

2020

Volltextzugriff (PDF)

Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?

Exploration of targeted anti-tumor therapy, 2023, Vol.4 (6), p.1301-1309

2023

Volltextzugriff (PDF)

A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers

Onco, 2023-05, Vol.3 (2), p.96-124

2023

Volltextzugriff (PDF)

Racial and Ethnic Disparities in Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy

Clinical genitourinary cancer, 2024-08, Vol.22 (4), p.102104, Article 102104

2024

Volltextzugriff (PDF)

Factors predicting pathological complete response in patients with localized breast cancer receiving neoadjuvant chemotherapy

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.165-165

2022

Volltextzugriff (PDF)

Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer

Immunotherapy, 2023-04, Vol.15 (6), p.397-400

2023

Volltextzugriff (PDF)

Geographic disparities in Medicare telehealth utilization and access to specialized cancer care in the United States

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13683-e13683

2023

Volltextzugriff (PDF)

The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability

Cell reports. Medicine, 2023-09, Vol.4 (9), p.101170-101170, Article 101170

2023

Volltextzugriff (PDF)

Impact of neuroendocrine tumor diagnosis (NET) on quality of life

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18614-e18614

2022

Volltextzugriff (PDF)

Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena

Cancer drug resistance, 2023-01, Vol.6 (3), p.642-55

2023

Volltextzugriff (PDF)

The role of lidocaine in cancer progression and patient survival

Pharmacology & therapeutics (Oxford), 2024-07, Vol.259, p.108654-108654, Article 108654

2024

Volltextzugriff (PDF)

CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer

Breast cancer research and treatment, 2024-07

2024

Volltextzugriff (PDF)

1 – 25 von 112

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(111)
Berichte
(1)

Sprache

Englisch
(112)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation

Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?

Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis

Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review

Effects of Immunotherapy on Quality-of-Life Outcomes in Patients with Gastroesophageal Cancers: A Meta-Analysis of Randomized Controlled Trials

Association between Environmental Temperature and Survival in Gastroesophageal Cancers: A Population Based Study

A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm

Targeting the tumor microenvironment to improve clinical outcomes in triple negative breast cancer patients and bridge the current disparity gap

Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient

Higher inflammatory response in hepatocellular carcinoma is associated with immune cell infiltration and a better outcome

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience

Predictors of Complete Pathological Response with Chemoimmunotherapy in Triple-Negative Breast Cancer: A Meta-Analysis

Undiagnosed Acquired Hemophilia A: Presenting as Recurrent Gastrointestinal Bleeding

Bad science in the time of COVID-19

Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?

A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers

Racial and Ethnic Disparities in Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy

Factors predicting pathological complete response in patients with localized breast cancer receiving neoadjuvant chemotherapy

Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer

Geographic disparities in Medicare telehealth utilization and access to specialized cancer care in the United States

The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability

Impact of neuroendocrine tumor diagnosis (NET) on quality of life

Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena

The role of lidocaine in cancer progression and patient survival

CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer

Suchergebnisse filtern